January 31st, 2014
A (Not So) New Drug Landscape for Pulmonary Arterial Hypertension
John Ryan, MD
John Ryan offers a primer on three newly approved drugs for pulmonary arterial hypertension.
NEJM Journal Watch — Recent Cardiology Articles- Benefit of Intravascular Imaging for Left Main PCI
- Mavacamten Therapy for Obstructive HCM — Do Women Respond Differently Than Men?
- Five-Year Results of TAVR vs. SAVR in Low-Risk Patients
- Atrial Fibrillation Risk Following Stroke from Large- or Small-Vessel Disease
- SGLT-2 Inhibitors and Acute Declines in Glomerular Filtration Rates